منابع مشابه
Ribonuclease-Activated Cancer Prodrug.
Cancer chemotherapeutic agents often have a narrow therapeutic index that challenges the maintenance of a safe and effective dose. Consistent plasma concentrations of a drug can be obtained by using a timed-release prodrug strategy. We reasoned that a ribonucleoside 3'-phosphate could serve as a pro-moiety that also increases the hydrophilicity of a cancer chemotherapeutic agent. Herein, we rep...
متن کاملProdrug Strategies for Paclitaxel
Paclitaxel is an anti-tumor agent with remarkable anti-tumor activity and wide clinical uses. However, it is also faced with various challenges especially for its poor water solubility and low selectivity for the target. To overcome these disadvantages of paclitaxel, approaches using small molecule modifications and macromolecule modifications have been developed by many research groups from al...
متن کاملCytomegalovirus Protease Targeted Prodrug Development
Human cytomegalovirus (HCMV) is a prevalent virus that infects up to 90% of the population. The goal of this research is to determine if small molecular prodrug substrates can be developed for a specific HCMV encoded protease and thus achieve site-specific activation. HCMV encodes a 256 amino acid serine protease that is responsible for capsid assembly, an essential process for herpes virus pro...
متن کاملProdrug Design vs. Drug Design
A drug is defined as a substance which is used in the cure, relief, diagnosis, treatment, or prevention of disease. The development of any potential drug commences with the study of the biochemistry and physiology behind a disease for which pharmaceutical intervention is feasible [1]. Prodrug is a term that was first introduced by Albert to signify a pharmacologically inactive chemical moiety t...
متن کاملSubstrate Mediated Enzyme Prodrug Therapy
In this report, we detail Substrate Mediated Enzyme Prodrug Therapy (SMEPT) as a novel approach in drug delivery which relies on enzyme-functionalized cell culture substrates to achieve a localized conversion of benign prodrug(s) into active therapeutics with subsequent delivery to adhering cells or adjacent tissues. For proof-of-concept SMEPT, we use surface adhered micro-structured physical h...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Ensho
سال: 1981
ISSN: 0389-4290,1884-4006
DOI: 10.2492/jsir1981.1.2_316